A series of studies demonstrated its oncogenic activity in the pathogenesis of HCC through various regulatory mechanisms such as activating advanced glycation end products (RAGE), mTOR pathway, as well as interacting with functional markers like HBX protein [18, 22, 39]. The gene discussed is MTOR; the disease is hepatocellular carcinoma.